Kang-Huai Wang - 01 Jul 2025 Form 3 Insider Report for CapsoVision, Inc (CV)

Signature
/s/ Tai Vivatvaraphol, Attorney-in-Fact for Kang-Huai Wang
Issuer symbol
CV
Transactions as of
01 Jul 2025
Net transactions value
$0
Form type
3
Filing time
01 Jul 2025, 21:39:36 UTC
Next filing
07 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wang Kang-Huai President and Chief Executive Officer Exhibit 24 - Power of Attorney, Director C/O CAPSOVISION, INC., 18805 COX AVENUE, SUITE 250, SARATOGA /s/ Tai Vivatvaraphol, Attorney-in-Fact for Kang-Huai Wang 01 Jul 2025 0002075513

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CV Common Stock 915,207 01 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CV Series A Preferred Stock 01 Jul 2025 Common Stock 1,407,407 Direct F2
holding CV Series C-1 Preferred Stock 01 Jul 2025 Common Stock 33,707 Direct F2
holding CV Series D Preferred Stock 01 Jul 2025 Common Stock 11,111 Direct F2
holding CV Series H Preferred Stock 01 Jul 2025 Common Stock 35,947 Direct F2
holding CV Stock Option (right to buy) 01 Jul 2025 Common Stock 3,334 $0.1100 Direct F3, F4
holding CV Stock Option (right to buy) 01 Jul 2025 Common Stock 11,459 $0.1100 Direct F4, F5
holding CV Stock Option (right to buy) 01 Jul 2025 Common Stock 887,500 $0.1700 Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Does not reflect a one-for-3.33 reverse stock split, to be effective immediately prior to the closing to the Issuer's initial public offering.
F2 Each share of Series A preferred stock, Series C-1 preferred stock, Series D preferred stock and Series H preferred stock (the "Preferred Stock") is convertible on a one-to-one basis into the underlying shares of common stock at the holder's election and has no expiration date. The Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 does not reflect a one-for-3.33 reverse stock split, to be effective immediately prior to the closing to the Issuer's initial public offering.
F3 The derivative security is fully vested as to the original number of underlying shares of common stock, which was 80,000 shares. Prior to July 1, 2025, the reporting person partially exercised the stock option and purchased 76,666 of the underlying shares which had vested.
F4 The number of underlying shares of common stock reported in Column 3 and the exercise price reported in Column 4 do not reflect a one-for-3.33 reverse stock split, to be effective immediately prior to the closing to the Issuer's initial public offering.
F5 The options vested as to 25% of the original number of underlying shares of common stock, which was 50,000 shares, on April 1, 2023 and as to the remaining 75% of the shares in 36 equal monthly installments thereafter through April 1, 2026, subject to continued service to the Issuer on each such date. The options, to the extent then outstanding and unvested, will vest in full upon a change in control of the Issuer. Prior to July 1, 2025, the reporting person partially exercised the stock option and purchased 38,541 of the underlying shares which had vested.
F6 The options vest as to 25% of the shares on November 1, 2025 and as to the remaining 75% of the shares in 36 equal monthly installments thereafter through November 1, 2028, subject to continued service to the Issuer on each such date. The options, to the extent then outstanding and unvested, will vest in full upon a change in control of the Issuer.

Remarks:

President and Chief Executive Officer Exhibit 24 - Power of Attorney